Background: rectal cancer (RC) is one of the most prevalent malignancies worldwide
comments, and finally 40 articles were fully reviewed. After scanning the full texts, 24 articles were excluded, including eight without raw data and 16 without crucial data. Finally, 16 eligible studies were included in this meta-analysis. Table 2 shows the basic information of the studies included in the meta-analysis. All included studies were published from 2001 to 2017, with a clinical tumor stage from cT2 to cT4, or UICC stage from II to III. Eight trials used chemotherapy (concurrent or adjuvant or both) in both groups, four trials only used chemotherapy (concurrent) in the LC group and two trials did not use chemotherapy. Four trials had a similar interval from the completion of radiation to the start of surgery in both groups. Two trials were performed in the Oceania region, eight in Europe, two in Asia, one in Africa and one in America.
Characteristics of enrolled studies

Analysis
For the analysis, PCR and tumor downstaging served as primary endpoints. Local recurrences, distant metastases, mortality and serious late toxicity served as secondary endpoints.
Primary endpoints
PCR rate
Ten studies (13, (15) (16) (17) (18) (19) (20) (21) (22) ) with a total of 1,569 patients reported PCR rate. As shown in the forest plot ( Fig. 2.1 ), significant heterogeneity (I 2 = 78%, p < 0.05) was observed.
Therefore a random effect model was applied. Although the LC group had a higher prevalence of PCR after therapy, the difference did not reach statistical significance (RR = 0.54, 95% CI: 0.26-1.10). On the other hand, according to the sensitivity analysis, the diamond of the pooled point would favor the LC group if the study by 
Tumor downstaging rate
Twelve studies (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) , with a total of 1,723 participants, reported a reduction in T or N stage based on the pretreatment clinical staging by CT or MRI versus the final pathological staging. As shown in figure 2.2, significant heterogeneity was observed (I 2 = 79%, p < 0.05) and a random effect model was applied. There was no statistical significance between the two groups (RR = 0.83, 95% CI: 0.58-1.17). However, the diamond of the pooled point would favor the LC group if the studies by Chung et al. (15) and Markovina et al. were excluded (21).
Secondary endpoints
Local recurrences and distant metastases
In terms of local recurrences, five studies (13, (15) (16) (17) ) with a total of 669 patients were included. Low heterogeneity was observed (I 2 = 22%, p = 0.27) and this was not statistically significant (RR = 0.55, 95% CI: 0.26-1.16). With regard to distant metastases, five studies (13, (15) (16) (17) ) with a total of 685 patients were included. Low heterogeneity was observed (I 2 = 29%, p = 0.22) and this was not statistically significant (RR = 1.03, 95% CI: 0.77-1.37). The results remained unchanged after the sensitivity analysis and the details are shown in figure 3.1 and 3.2.
Mortality
Six studies (13, 15, 17, 18, 23, 26 ) with a total of 1,309 patients reported mortality.
There was no heterogeneity (I 2 = 0%, p = 0.78) and this was not statistically significant (RR = 0.95, 95% CI: 0.78-1.15). The results remained unchanged after the sensitivity analysis and the details are shown in figure 3.3.
Serious late toxicity
Four studies (13, 22, 25, 27) , with a total of 792 rectal cancer patients, reported serious late toxicity. Significant heterogeneity was observed (I 2 = 74%, p = 0.01) and therefore the random effect model was used. No statistical difference was found between the two groups (RR = 1.10, 95% CI: 0.37-3.26). The details are shown in figure 3 .4.
Subgroup analysis
A subgroup analysis was performed based on study types and the use of chemotherapy (CT) in order to deliver a more accurate result and reduce the impact of high heterogeneity. In the first category, studies were stratified into RCTs and
CCTs. LC had a higher prevalence of PCR and tumor downstaging than SC in the RCTs subgroup (RR = 0.18, 95% CI: 0.09-0.37; RR = 0.67, 95% CI: 0.54-0.82) and less heterogeneity was also observed (I 2 = 21%, p = 0.28; I 2 = 0%, p = 0.50). No significant difference was observed in the local recurrences, distant metastases, mortality and serious late toxicity subgroups.
In the second category, the analysis was stratified into three subgroups: LC and SC with chemotherapy (both CT), no chemotherapy in the SC group (SC non-CT) and no chemotherapy in both groups (both non-CT). The SC group had a poorer PCR rate A subgroup analysis was performed based on study types and intervention with chemotherapy due to the significant heterogeneity within the meta-analysis. The results show that the LC group had a higher prevalence of PCR and tumor downstaging in the RCT subgroup, which are consistent with previous studies.
Furthermore, the LC group also had a higher prevalence of PCR compared with the SC group without chemotherapy, which suggests that PCR may correlate with chemotherapy. Several randomized trials by EORTC (34) and the Foundation Francaise de Cancerologie (35) have confirmed the benefit of chemotherapy for local control, PCR and tumor downstaging (6,13,35,36). Nevertheless, some studies have also revealed that chemotherapy was associated with grade 3 or 4 toxicity (13) .
Some limitations within this study should not be ignored. Firstly, we combined RCTs and CCTs in the meta-analysis, which may lead to a notable heterogeneity in the overall analysis. Secondly, there were different types of surgery performed in the various studies; some studies performed TME while others adopted APR, LAR or
Hartmann surgery, which may lead to bias. Thirdly, clinical staging is based on diagnostic imaging tests which may not be as accurate as histopathological staging.
Finally, few studies reported the quality of TME and circumferential margin, therefore the influence of these variables cannot be evaluated.
On the basis of our findings, it can be concluded that both LC and SC therapies are effective and safe for the treatment of locally advanced disease with regard to PCR rate, tumor downstaging rate, local recurrence, distant metastases, mortality and serious late toxicity. Furthermore, chemotherapy may lead to a better PCR rate.
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